Who are TRACON Pharmaceuticals's investors?

TRACON Pharmaceuticals's investors include New Enterprise Associates (NEA), Runway Growth Capital.

How much funding has TRACON Pharmaceuticals raised?

TRACON Pharmaceuticals has disclosed $39.7M raised across 2 rounds.

Where is TRACON Pharmaceuticals headquartered?

TRACON Pharmaceuticals is headquartered in San Diego, US.

TRACON Pharmaceuticals

San Diego, US · Delaware corporation · 11 employees on LinkedIn · 2 known investors

Find your way into TRACON Pharmaceuticals

241 people in our graph share verified history with the TRACON Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

Antonio Turroniunlockedknows H CASEY LOGAN · together at Northwestern University - Kellogg School of Management (overlapped)

×4knows the team · via University of Michigan

×7knows the team · via Northwestern University - Kellogg School of Management

TRACON Pharmaceuticals was a biopharmaceutical company that is currently undergoing liquidation and dissolution as of November 2024.

Biotech

Founders & leadership

H CASEY LOGAN inChief Business Officer2013–2018Executive officer at TRACON Pharmaceuticals with 25 years of experience in pharmaceutical business development, strategic planning, and M&A activities.

CHARLES P. THEUERinCEO

PATRICIA L. BITARExecutive

Board

PAUL WALKERBoard directorPartner, Co-Head of Healthcare at New Enterprise Associates (NEA)

STEPHEN WORLANDBoard director

WILLIAM LARUEBoard director

J. RAINER TWIFORDBoard director

MARTIN MATTINGLYBoard director

Investors · 2

New Enterprise Associates (NEA)Menlo Park · $200K – $40M

Runway Growth CapitalMenlo Park · $10M – $150M

Reported raises · per SEC filings

Form D private placements

$39.7M disclosed across 2 rounds · 2017–2018

▶$38.7MraisedApr 2018 · 11 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

J. RAINER TWIFORDDirector
PAUL WALKERDirector
TED WANGDirector
WILLIAM LARUEDirector
CHARLES P. THEUERExecutive Officer, Director
PATRICIA L. BITARExecutive Officer
STEPHEN WORLANDDirector
MARTIN MATTINGLYDirector

Offering amount: $75.7M
Amount sold: $38.7M
Sales commissions: $2M
Placement agents: Angel Pond Capital LLC, LifeSci Capital
First sale: Mar 2018
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1MraisedMay 2017 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

STEPHEN WORLANDDirector
WILLIAM LARUEDirector
J. RAINER TWIFORDDirector
H CASEY LOGANExecutive Officer
CHARLES P. THEUERExecutive Officer, Director
PATRICIA L. BITARExecutive Officer
MARTIN MATTINGLYDirector
PAUL WALKERDirector

Offering amount: $21M
Amount sold: $1M
First sale: Mar 2017
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does TRACON Pharmaceuticals do?: TRACON Pharmaceuticals was a biopharmaceutical company that is currently undergoing liquidation and dissolution as of November 2024.
Who are TRACON Pharmaceuticals's investors?: TRACON Pharmaceuticals's investors include New Enterprise Associates (NEA), Runway Growth Capital.
How much funding has TRACON Pharmaceuticals raised?: TRACON Pharmaceuticals has disclosed $39.7M raised across 2 rounds.
Where is TRACON Pharmaceuticals headquartered?: TRACON Pharmaceuticals is headquartered in San Diego, US.